Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aCCeleR8-001 of S-531011 alone and with an immune checkpoint inhibitor in advanced solid tumors
jRCT2031210426Phase 2Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of S-531011 in Nonhematologic neoplasms, colorectal cancer (CRC), melanoma and 10 more (5 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Number of participants with treatment-emergent adverse events, Objective response rate and 5 more. Started May 2022; status: recruiting.
02
Drugs
S-531011
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)melanomahead and neck squamous cell carcinoma (HNSCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT2031210426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210426.